Article Text

Download PDFPDF

Original research
Impact of preinterventional tricuspid regurgitation on outcome of MitraClip therapy in patients with severely reduced ejection fraction
  1. Takayuki Gyoten1,
  2. Daniel Messroghli2,3,
  3. Soeren Schenk1,
  4. Kristin Rochor1,
  5. Oliver Grimmig1,
  6. Soeren Just1 and
  7. Dirk Fritzsche1
  1. 1Cardiac Surgery, Sana-Herzzentrum Cottbus, Cottbus, Brandenburg, Germany
  2. 2Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
  3. 3Internal Medicine and Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany
  1. Correspondence to Dr Takayuki Gyoten; t.gyoten29{at}


Aim To evaluate the impact of preinterventional moderate-to-severe functional tricuspid regurgitation (FTR) on early outcome after percutaneous edge-to-edge mitral valve repair (pMVR) with MitraClip procedures for functional mitral regurgitation (FMR) in patients with heart failure with reduced ejection fraction (HFrEF).

Methods and results From January 2013 to December 2017, 80 patients with HFrEF (ejection fraction 22%±5.3%) and FMR (grade 3.0±0.36) underwent successful pMVR. The 3-year actuarial survival was 58%. However, 73% (n=22) of non-survivors died of cardiac failure within 1 year. Patients were categorised into none-to-mild (n=36) and moderate-to-severe (n=44) postinterventional FTR groups according to pre-MitraClip tricuspid regurgitation grade. Cox regression analysis on 1-year survival demonstrated an impact of FTR severity (HR=1.8, 95% CI 1.01% to 3.09%, p=0.047), preoperative New York Heart Association class (HR=2.8, 95% CI 1.2% to 6.5%, p=0.015) and peripheral artery disease (HR=5.4, 95% CI 1.6 to 18, p=0.0054). Kaplan-Meier analysis showed that 1-year cardiac death was higher in the moderate-to-severe FTR group (p=0.048). In our study, 77% of pre-MitraClip moderate-to-severe FTR cannot be significantly reduced. Post-MitraClip moderate-to-severe FTR grade was related to lower survival (p<0.001).

Conclusion In patients with HFrEF treated with MitraClip for FMR, moderate-to-severe FTR was an independent predictor of cardiac death within 1 year. To improve survival, additional therapy to residual FTR should be considered in early phase after MitraClip therapy.

  • tricuspid valve disease
  • mitral regurgitation
  • cardiac surgery
  • heart failure

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors All persons who meet the authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in Open Heart. TG, DM: conception or design of the work, and acquisition, analysis and interpretation of data for the work. SS, KR, OG, SJ: conception or design of the work, and agreement to be accountable for all aspects of the work. DF, DM: final approval of the version to be published and agreement to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval This single-centre study was approved by the Institutional Review Board of Sana Heart Center in Cottbus (Germany). The study complied with the Declaration of Helsinki. The study protocol was discussed with local ethics authorities (Ärztekammer Brandenburg, Germany), and ethical approval was waived due to the retrospective design of the study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available in a public, open access repository. Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. Upon receiving approval from the Institutional Review Board of the Sana Heart Center, we retrospectively reviewed the records of consecutive patients who, between January 2013 and January 2018, had undergone medication therapy alone, repeat MitraClip therapy, or surgical revision for persistent or recurrent MR after percutaneous MitraClip therapy.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.